Human papillomavirus vaccine - MediGene/Virionics

Drug Profile

Human papillomavirus vaccine - MediGene/Virionics

Alternative Names: CVLP tumour vaccine - MediGene/Virionics; HPV-16 L1-E7 chimeric VLP - MediGene/Virionics; Human papillomavirus type 16 L1-E7 chimeric virus-like particle vaccine - MediGene/Virionics; PapViRx

Latest Information Update: 30 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MediGene AG
  • Developer MediGene AG; Virionics
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Anal intraepithelial neoplasia; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections; Vulvar intraepithelial neoplasia

Most Recent Events

  • 11 Mar 2008 Preclinical trials in Cervical intraepithelial neoplasia in USA (unspecified route)
  • 11 Mar 2008 Preclinical trials in Human papillomavirus infections in USA (unspecified route)
  • 04 Apr 2006 Human papillomavirus vaccine licensed to Virionics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top